Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 3
Submit an article Journal homepage
794
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)

Meletios A. DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-8990-3254View further author information
ORCID Icon,
Michele CavoDepartment of Experimental, Diagnostic and Specialty Medicine, “Seragnoli” Institute of Hematology, University of Bologna, Bologna, Italy; View further author information
,
Maria-Victoria MateosDepartment of Hematology, University Hospital of Salamanca/IBSAL, Salamanca, Spain; ORCID Iconhttp://orcid.org/0000-0003-2390-1218View further author information
ORCID Icon,
Thierry FaconDepartment of Hematology, University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; View further author information
,
Bart HeegIngress Health, Rotterdam, The Netherlands; ORCID Iconhttp://orcid.org/0000-0002-9226-3232View further author information
ORCID Icon,
Sophie van BeekhuizenIngress Health, Rotterdam, The Netherlands; View further author information
,
Samron B. GebregergishIngress Health, Rotterdam, The Netherlands; View further author information
,
Sandhya NairJanssen Research and Development, Beerse, Belgium; View further author information
,
Marta PisiniJanssen, EMEA, Beerse, Belgium; View further author information
,
Annette LamJanssen Global Services, Raritan, NJ, USAORCID Iconhttp://orcid.org/0000-0003-2037-3464View further author information
ORCID Icon &
Mary SlavcevJanssen Global Services, Raritan, NJ, USAView further author information
 show all
Pages 714-720 | Received 28 Jun 2019, Accepted 13 Oct 2019, Published online: 05 Nov 2019

References

  • Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl. 4):iv52–iv61.
  • Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103(2):197–211.
  • Engelhardt M, Terpos E, Kleber M, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99(2):232–242.
  • Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–917.
  • Palumbo A, Bringhen S, Rossi D, et al. Bortezomib–melphalan–prednisone–thalidomide followed by maintenance with bortezomib–thalidomide compared with bortezomib–melphalan–prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101–5109.
  • San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–917.
  • Hulin C, Belch A, Shustik C, et al. Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol. 2016;34(30):3609–3617.
  • Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301–310.
  • Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124(21):3474.
  • Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–321.
  • van de Donk N, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270(1):95–112.
  • Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394.
  • Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking. J Immunol. 2016;197(3):807–813.
  • DARZALEX™ (daratumumab) injection, for intravenous use [package insert]. Horsham (PA): Janssen Biotech, Inc.; 2018.
  • Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528.
  • Genmab. Genmab announces European Marketing Authorization for DARZALEX® (daratumumab) for front line multiple myeloma; [cited 2018 Sep 14]. Available from: https://ir.genmab.com/news-releases/news-release-details/genmab-announces-european-marketing-authorization-darzalexr-0
  • van Beurden-Tan CH, Franken MG, Blommestein HM, et al. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma. J Clin Oncol. 2017;35(12):1313–1319.
  • Botta C, Ciliberto D, Rossi M, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. Blood Adv. 2017;1(7):455–466.
  • San-Miguel J, Facon T, Dimopoulos MA, et al. Treatment regimens for patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: a systematic literature review and network meta-analysis. Poster presented at: The International Society for Pharmacoeconomics Outcomes Research 2018 European Meeting (ISPOR EU); 2018 Nov 10–14; Barcelona, Spain.
  • Moreau P, San MJ, Ludwig H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 (Suppl. 6):vi133–vi137.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Multiple myeloma. version 1; 2019; [cited 2018 Oct 19]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
  • Signorovitch J, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
  • Guyot P, Ades AE, Ouwens JNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12(1):2–13.
  • Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.